Scholarlink

<p>Numerous nosocomial infections were observed in hospitals and other healthcare facilities during the COVID-19 pandemic, largely attributed to asymptomatic or pre-symptomatic carriers. SARS-CoV-2 screening data at admission of all hospitalised patients and accompanying persons of a tertiary-care hospital in Germany was included from 1 April 2020 to 31 December 2021. The first oropharyngeal swab of each newly admitted individual was tested for SARS-CoV-2 RNA using reverse transcription polymerase chain reaction (RT-qPCR). The overall testing costs and the costs per positively tested individual were analysed. Out of 111,271 screened individuals, 705 (0.6%) tested positive for SARS-CoV-2 by RT-qPCR. Among these, 236 cases (0.2%) had not been previously diagnosed and were identified through RT-qPCR admission screening. Of the newly detected cases,110 (0.1%) were asymptomatic without any known positive contact history. The specificity of RT-qPCR in screening use was 99.997% (95% CI 99.992–99.999%). The mean testing costs of identifying one SARS-CoV-2-positive individual through admission screening was €8,082.87. Long-term universal RT-qPCR admission screening detected a substantial number of otherwise unidentified SARS-CoV-2-positive individuals, proving its value as a infection control tool with an excellent specificity in screening use during the COVID-19 pandemic. This strategy represents an important lesson learned from the pandemic and may serve as a valuable infection control tool for future pandemics or seasonal pathogen surges.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Universal SARS-CoV-2 RT-qPCR admission screening over 21 months in a German tertiary care hospital: detection of asymptomatic infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • Isabella Eiter,
  • Till Gallasch,
  • Sören Krüger,
  • Michael Eisenmann,
  • Vera Rauschenberger,
  • Anna Höhn,
  • Sina Ebert,
  • Kerstin Knies,
  • Christiane Prifert,
  • Benedikt Weißbrich,
  • Lars Dölken,
  • Stefanie Kampmeier,
  • Isabell Wagenhäuser,
  • Manuel Krone

摘要

Numerous nosocomial infections were observed in hospitals and other healthcare facilities during the COVID-19 pandemic, largely attributed to asymptomatic or pre-symptomatic carriers. SARS-CoV-2 screening data at admission of all hospitalised patients and accompanying persons of a tertiary-care hospital in Germany was included from 1 April 2020 to 31 December 2021. The first oropharyngeal swab of each newly admitted individual was tested for SARS-CoV-2 RNA using reverse transcription polymerase chain reaction (RT-qPCR). The overall testing costs and the costs per positively tested individual were analysed. Out of 111,271 screened individuals, 705 (0.6%) tested positive for SARS-CoV-2 by RT-qPCR. Among these, 236 cases (0.2%) had not been previously diagnosed and were identified through RT-qPCR admission screening. Of the newly detected cases,110 (0.1%) were asymptomatic without any known positive contact history. The specificity of RT-qPCR in screening use was 99.997% (95% CI 99.992–99.999%). The mean testing costs of identifying one SARS-CoV-2-positive individual through admission screening was €8,082.87. Long-term universal RT-qPCR admission screening detected a substantial number of otherwise unidentified SARS-CoV-2-positive individuals, proving its value as a infection control tool with an excellent specificity in screening use during the COVID-19 pandemic. This strategy represents an important lesson learned from the pandemic and may serve as a valuable infection control tool for future pandemics or seasonal pathogen surges.